Eun Yang

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.  With the IPO quiet period expiring, analysts are starting coverage of the stock — and adopting a bullish...

Jefferies and Citigroup initiated coverage for NuCana PLC (ADR) (NASDAQ: NCNA) Monday with a Buy rating and a price target of $25 and $23 respectively. Jefferies' analysts Eun Yang and Carmen Augustine explained that the company is focused on developing safer and more potent chemotherapies for...

The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference. Here’s a breakdown of the highlights. Five Prime Therapeutics Five Prime Therapeutics Inc (NASDAQ: FPRX) reported positive...

The U.S. Food and Drug Administration approved in late December Ionis Pharmaceuticals Inc's (NASDAQ: IONS) therapy for the treatment of spinal muscular atrophy called Spinraza. In a research report on Friday, Jefferies' Eun Yang suggested that Spinraza is Ionis' only exciting...

Shares of Array Biopharma Inc (NASDAQ: ARRY) continue its bull run Tuesday, climbing more than 6 percent after surging 81 percent Monday on the heels of its positive late-stage skin cancer trial results. The study evaluating encorafenib and binimetinib in patients with "untreaded or 1L...